Targeting a patient population in the millions, Cambridge, MA-based Genocea this week released results of its genital herpes vaccine hopeful that CEO Chip Clark says affirm the jab's potential to one day break the $1 billion sales mark.
Fresh off of a $55 million Series A financing round, Neon Therapeutics jumped into the cancer vaccines space today with the aim of utilizing neoantigen biology to unlock a powerful immune response against the disease. Read more >>
Just 5 months after it scored $21 million of a potential $45 million grant for the development of Ebola treatments, Inovio Pharmaceuticals picked up the remaining $24 million from DARPA, the company announced on Monday. The DOD's Defense Advanced Research Projects Agency chose Inovio to lead the development of Ebola treatments and preventive measures, including a DNA-based vaccine against the disease. Read more >>
POPULAR COMMENT THREADS
On Sept. 18, Advaxis reported "encouraging" data from a Phase II trial of its cervical cancer vaccine, axalimogene filolisbac, dubbed ADXS-HPV. Now, the biotech is reporting an FDA clinical hold on the candidate--5 days after the FDA placed the hold.
In a potential boost to uptake and adherence, Pfizer reported promising data this week on its meningitis B vaccine Trumenba administered concomitantly with Menactra and Adacel from Sanofi Pasteur.
Just three weeks after it struck up a $28.5 million government partnership to advance its Ebola vaccine, Johnson & Johnson announced on Friday that it is starting a safety and immunogenicity trial in Sierra Leone for its Ebola candidate.
Building on an existing relationship, Indian generics giant Cipla and vaccines outfit Serum Institute of India on Thursday announced a collaboration to bring Serum's vaccines to South Africa.
In a move to ease antitrust concerns ahead of its multibillion-dollar asset swap with Novartis, GlaxoSmithKline announced in June that it would sell two of its mature meningitis jabs to Pfizer.
The race to a Clostridium difficile vaccine has been dominated by Big Pharmas Sanofi and Pfizer, whose candidates were fast-tracked by the FDA in 2010 and 2014, respectively. Allegheny General Hospital in Pittsburgh announced on Wednesday that it will participate in Phase III trials for Sanofi's investigational vaccine.
From Our Sister Sites
Moderna Therapeutics' top scientist has quietly left the much-discussed company after two years at the helm of its R&D operation, walking away from a cash-flush biotech with big ambitions.
A new company spun out of Harvard University's Wyss Institute raised $5.15 million in Series A cash to develop a technology its founders say can generate images of unprecedented resolution, creating a new avenue for diagnostics and drug discovery.